Addressing the Cold Reality of mRNA Vaccine Stability.
Reads0
Chats0
TLDR
It is concluded that systematic approaches to identify the key physicochemical degradation mechanism(s) of formulated mRNA vaccine candidates are currently lacking and rational design of optimally stabilized mRNA vaccine formulations during storage, transport, and administration at refrigerated or ambient temperatures should have top priority in the pharmaceutical development community.About:
This article is published in Journal of Pharmaceutical Sciences.The article was published on 2021-03-01 and is currently open access. It has received 252 citations till now. The article focuses on the topics: Vaccine Potency.read more
Citations
More filters
Journal ArticleDOI
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
Linde Schoenmaker,Dominik Witzigmann,Jayesh A. Kulkarni,Rein Verbeke,Gideon F.A. Kersten,Wim Jiskoot,Daan J.A. Crommelin +6 more
TL;DR: In this article, the authors discuss the structure of mRNA-LNPs, factors that impact their stability, and strategies to optimize them to improve the product stability of COVID-19 vaccines.
Journal ArticleDOI
mRNA vaccine for cancer immunotherapy.
Lei Miao,Yu Zhang,Leaf Huang +2 more
TL;DR: A detailed overview of the recent progress and existing challenges of mRNA cancer vaccines and future considerations of applying mRNA vaccine for cancer immunotherapies is provided in this article, where a detailed review of mRNA vaccine applications is presented.
Journal ArticleDOI
mRNA vaccines for COVID-19: what, why and how.
Abstract: The Coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2), has impacted human lives in the most profound ways with millions of infections and deaths. Scientists and pharmaceutical companies have been in race to produce vaccines against SARS-CoV-2. Vaccine generation usually demands years of developing and testing for efficacy and safety. However, it only took less than one year to generate two mRNA vaccines from their development to deployment. The rapid production time, cost-effectiveness, versatility in vaccine design, and clinically proven ability to induce cellular and humoral immune response have crowned mRNA vaccines with spotlights as most promising vaccine candidates in the fight against the pandemic. In this review, we discuss the general principles of mRNA vaccine design and working mechanisms of the vaccines, and provide an up-to-date summary of pre-clinical and clinical trials on seven anti-COVID-19 mRNA candidate vaccines, with the focus on the two mRNA vaccines already licensed for vaccination. In addition, we highlight the key strategies in designing mRNA vaccines to maximize the expression of immunogens and avoid intrinsic innate immune response. We also provide some perspective for future vaccine development against COVID-19 and other pathogens.
Journal ArticleDOI
The clinical progress of mRNA vaccines and immunotherapies
TL;DR: The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of the viral sequence highlights the transformative potential of this nucleic acid technology as mentioned in this paper .
Journal ArticleDOI
Lipids and Lipid Derivatives for RNA Delivery
TL;DR: In this article, a review of lipid-based RNA delivery systems is presented, focusing mainly on their chemical structures, synthetic routes, characterization, formulation methods, and structure-activity relationships.
References
More filters
Journal ArticleDOI
mRNA vaccines — a new era in vaccinology
TL;DR: A detailed overview of mRNA vaccines is provided and future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use are considered.
Journal ArticleDOI
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.
TL;DR: The challenges for clinical translation of RNA-based therapeutics are discussed, with an emphasis on recent advances in biomaterials and delivery strategies, and an overview of the applications of mRNA-based delivery for protein therapy, gene editing, and vaccination are presented.
Journal ArticleDOI
Advances in the delivery of RNA therapeutics: from concept to clinical reality.
TL;DR: The challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, are discussed, and an overview of the applications of RNAs for modulation of gene/protein expression and genome editing that are currently being investigated both in the laboratory as well as in the clinic are presented.
Journal ArticleDOI
mRNA vaccine delivery using lipid nanoparticles.
TL;DR: Among potential nonviral vectors, lipid nanoparticles are particularly promising, and can be synthesized with relative ease in a scalable manner, protect the mRNA against degradation, facilitate endosomal escape, and as needed, can be codelivered with adjuvants.
Journal ArticleDOI
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Kimberly J. Hassett,Kerry Benenato,Eric Jacquinet,Aisha Lee,Angela Woods,Olga Yuzhakov,Sunny Himansu,Jessica Deterling,Benjamin M. Geilich,Tatiana Ketova,Cosmin Mihai,Andy Lynn,Iain Mcfadyen,Melissa J. Moore,Joseph J. Senn,Matthew G. Stanton,Orn Almarsson,Giuseppe Ciaramella,Luis Brito +18 more
TL;DR: Screening a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model shows that mRNA vaccine tolerability can be improved without affecting potency.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
mRNA-based therapeutics — developing a new class of drugs
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson,Evan J. Anderson,Nadine Rouphael,Paul C. Roberts,Mamodikoe Makhene,Rhea N. Coler,Michele Paine McCullough,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Nicole A. Doria-Rose,Kizzmekia S. Corbett,Kaitlyn M. Morabito,Sijy O’Dell,Stephen D. Schmidt,Phillip A. Swanson,Marcelino Padilla,John R. Mascola,Kathleen M. Neuzil,Hamilton Bennett,Wellington Sun,Etza Peters,Mat Makowski,Jim Albert,Kaitlyn Cross,Wendy Buchanan,Rhonda Pikaart-Tautges,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +32 more